최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.29 no.2, 2019년, pp.109 - 114
Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests as joint damage or athletic disability via sustained inflammation of the synovial membrane. The risk of cardiovascular disease (CVD) is higher in RA patients. This study aimed at evaluating the association betwee...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
류마티스관절염은 어떤 조건에서 더 빈번하게 발생되는가? | 류마티스관절염(rheumatoid arthritis, RA)은 관절 활막의 지속적인 염증반응을 통해 관절손상이나 운동능력 장애를 나타내는 염증성 전신질환으로, 1) 일반적으로 약 1% 정도의 유병율로 발병한다고 알려져있다. 2,3) 환자의 특성으로 분류하였을 때는 여성에서 보다 빈번하게 나타나며, 연령과 상관없이 발병할 수 있으나 고령이 될 수록 성별에 따른 발병 빈도차이는 감소한다. 4) 또한 환자의 신체적 특징 외에도 사회경제적 여건 이 낮은 계층에서 더 많이 발병한다. 5) | |
류마티스관절염이란? | 류마티스관절염(rheumatoid arthritis, RA)은 관절 활막의 지속적인 염증반응을 통해 관절손상이나 운동능력 장애를 나타내는 염증성 전신질환으로, 1) 일반적으로 약 1% 정도의 유병율로 발병한다고 알려져있다. 2,3) 환자의 특성으로 분류하였을 때는 여성에서 보다 빈번하게 나타나며, 연령과 상관없이 발병할 수 있으나 고령이 될 수록 성별에 따른 발병 빈도차이는 감소한다. | |
류마티스관절염의 유병율은 어떻게 되는가? | 류마티스관절염(rheumatoid arthritis, RA)은 관절 활막의 지속적인 염증반응을 통해 관절손상이나 운동능력 장애를 나타내는 염증성 전신질환으로, 1) 일반적으로 약 1% 정도의 유병율로 발병한다고 알려져있다. 2,3) 환자의 특성으로 분류하였을 때는 여성에서 보다 빈번하게 나타나며, 연령과 상관없이 발병할 수 있으나 고령이 될 수록 성별에 따른 발병 빈도차이는 감소한다. |
Scott, D.L., Wolfe, F., Huizinga, T.W.. Rheumatoid arthritis. The Lancet, vol.376, no.9746, 1094-1108.
Silman, Alan J, Pearson, Jacqueline E. Epidemiology and genetics of rheumatoid arthritis. Arthritis research, vol.4, no.suppl3, S265-S272.
Hunter, Theresa M., Boytsov, Natalie N., Zhang, Xiang, Schroeder, Krista, Michaud, Kaleb, Araujo, Andre B.. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatology international, vol.37, no.9, 1551-1557.
Minichiello, E., Semerano, L., Boissier, M.C.. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. Joint, bone, spine : revue du rhumatisme, vol.83, no.6, 625-630.
Naqvi AA, Hassali MA, Aftab MT. Epidemiology of rheumatoid arthritis, clinical aspects and socio-economic determinants in Pakistani patients:A systematic review and meta-analysis. J Pak Med Assoc 2019;69:389-98.
Sandoo, Aamer, Chanchlani, Neil, Hodson, James, Smith, Jacqueline P, Douglas, Karen M, Kitas, George D. Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. Arthritis research & therapy, vol.15, no.6, R203-R203.
Liao, K.P.. Cardiovascular disease in patients with rheumatoid arthritis. Trends in cardiovascular medicine, vol.27, no.2, 136-140.
Arts, Elke EA, Fransen, Jaap, Den Broeder, Alfons A, van Riel, Piet L C M, Popa, Calin D. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Annals of the rheumatic diseases : the official journal, vol.76, no.10, 1693-1699.
Solomon, D. H., Reed, G. W., Kremer, J. M., Curtis, J. R., Farkouh, M. E., Harrold, L. R., Hochberg, M. C., Tsao, P., Greenberg, J. D.. Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events. Arthritis & rheumatology, vol.67, no.6, 1449-1455.
Ljung, Lotta, Rantapaa-Dahlqvist, Solbritt, Jacobsson, Lennart T H, Askling, Johan. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Annals of the rheumatic diseases : the official journal, vol.75, no.12, 2087-2094.
Rempenault, Claire, Combe, Bernard, Barnetche, Thomas, Gaujoux-Viala, Cécile, Lukas, Céédric, Morel, Jacques, Hua, Charlotte. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Annals of the rheumatic diseases : the official journal, vol.77, no.1, 98-103.
Saag, Kenneth G., Teng, Gim Gee, Patkar, Nivedita M., Anuntiyo, Jeremy, Finney, Catherine, Curtis, Jeffrey R., Paulus, Harold E., Mudano, Amy, Pisu, Maria, Elkins-Melton, Mary, Outman, Ryan, Allison, Jeroan J., Almazor, Maria Suarez, Bridges Jr., S. Louis, Chatham, W. Winn, Hochberg, Marc, Maclean, Catherine, Mikuls, Ted, Moreland, Larry W., O'dell, James, Turkiewicz, Anthony M., Furst, Daniel E.. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and rheumatism, vol.59, no.6, 762-784.
Singh, Jasvinder A., Saag, Kenneth G., Bridges Jr., S. Louis, Akl, Elie A., Bannuru, Raveendhara R., Sullivan, Matthew C., Vaysbrot, Elizaveta, McNaughton, Christine, Osani, Mikala, Shmerling, Robert H., Curtis, Jeffrey R., Furst, Daniel E., Parks, Deborah, Kavanaugh, Arthur, O'Dell, James, King, Charles, Leong, Amye, Matteson, Eric L., Schousboe, John T., Drevlow, Barbara, Ginsberg, Seth, Grober, James, St.Clair, E. William, Tindall, Elizabeth, Miller, Amy S., McAlindon, Timothy. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care & research, vol.68, no.1, 1-25.
Singh, Jasvinder A., Furst, Daniel E., Bharat, Aseem, Curtis, Jeffrey R., Kavanaugh, Arthur F., Kremer, Joel M., Moreland, Larry W., O'Dell, James, Winthrop, Kevin L., Beukelman, Timothy, Bridges Jr., S. Louis, Chatham, W. Winn, Paulus, Harold E., Suarez‐almazor, Maria, Bombardier, Claire, Dougados, Maxime, Khanna, Dinesh, King, Charles M., Leong, Amye L., Matteson, Eric L., Schousboe, John T., Moynihan, Eileen, Kolba, Karen S., Jain, Archana, Volkmann, Elizabeth R., Agrawal, Harsh, Bae, Sangmee, Mudano, Amy S., Patkar, Nivedita M., Saag, Kenneth G.. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis care & research, vol.64, no.5, 625-639.
Micha, Renata, Imamura, Fumiaki, Wyler von Ballmoos, Moritz, Solomon, Daniel H., Hernán, Miguel A., Ridker, Paul M., Mozaffarian, Dariush. Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. The American journal of cardiology, vol.108, no.9, 1362-1370.
O'Neill, Francis, Charakida, Marietta, Topham, Eric, McLoughlin, Eve, Patel, Neha, Sutill, Emma, Kay, Christopher W M, D'Aiuto, Francesco, Landmesser, Ulf, Taylor, Peter C, Deanfield, John. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart : official journal of the British Cardiac Society, vol.103, no.10, 766-773.
Agca, R, Heslinga, S C, Rollefstad, S, Heslinga, M, McInnes, I B, Peters, M J L, Kvien, T K, Dougados, M, Radner, H, Atzeni, F, Primdahl, J, Sodergren, A, Wallberg Jonsson, S, van Rompay, J, Zabalan, C, Pedersen, T R, Jacobsson, L, de Vlam, K, Gonzalez-Gay, M A, Semb, A G, Kitas, G D, Smulders, Y M, Szekanecz, Z, Sattar, N, Symmons, D P M, Nurmohamed, M T. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the rheumatic diseases : the official journal, vol.76, no.1, 17-28.
Boo, Sunjoo, Oh, Hyunjin, Froelicher, Erika S., Suh, Chang-Hee. Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis. PloS one, vol.12, no.4, e0176291-.
Kim, Logyoung, Kim, Jee-Ae, Kim, Sanghyun. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiology and health, vol.36, e2014008-.
Robertson, Jamie, Peters, Mike J., McInnes, Iain B., Sattar, Naveed. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature reviews. Rheumatology, vol.9, no.9, 513-523.
van Sijl, A.M., Peters, M.J.L., Knol, D.L., de Vet, R.H.C., Sattar, N., Dijkmans, B.A.C., Smulders, Y.M., Nurmohamed, M.T.. The Effect of TNF-alpha Blocking Therapy on Lipid Levels in Rheumatoid Arthritis: A Meta-Analysis. Seminars in arthritis and rheumatism, vol.41, no.3, 393-400.
Choi, Hyon K, Hernán, Miguel A, Seeger, John D, Robins, James M, Wolfe, Frederick. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. The Lancet, vol.359, no.9313, 1173-1177.
Greenberg, Jeffrey D, Kremer, Joel M, Curtis, Jeffrey R, Hochberg, Marc C, Reed, George, Tsao, Peter, Farkouh, Michael E, Nasir, Adeel, Setoguchi, Soko, Solomon, Daniel H. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Annals of the rheumatic diseases : the official journal, vol.70, no.4, 576-582.
Barnabe, Cheryl, Martin, Billie‐Jean, Ghali, William A.. Systematic review and meta‐analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis care & research, vol.63, no.4, 522-529.
Dierkes, Jutta, Westphal, Sabine. Effect of drugs on homocysteine concentrations.. Seminars in vascular medicine, vol.5, no.2, 124-139.
Merkle, Carrie J., Moore, Ida M. (Ki), Penton, Beau S., Torres, Bonny J., Cueny, Renee K., Schaeffer Jr., Richard C., Montgomery, David W.. Methotrexate Causes Apoptosis in Postmitotic Endothelial Cells. Biological research for nursing, vol.2, no.1, 5-14.
Lim, Debbie T., Cannella, Amy C., Michaud, Kaleb D, Mikuls, Ted R.. Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis. Current rheumatology reports, vol.16, no.11, 459-.
Aviña-Zubieta, J. Antonio, Choi, Hyon K., Sadatsafavi, Mohsen, Etminan, Mahyar, Esdaile, John M., Lacaille, Diane. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis and rheumatism, vol.59, no.12, 1690-1697.
Nicola, Paulo J., Crowson, Cynthia S., Maradit-Kremers, Hilal, Ballman, Karla V., Roger, Véronique L., Jacobsen, Steven J., Gabriel, Sherine E.. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis and rheumatism, vol.54, no.1, 60-67.
Schmidt, Timothy J., Aviña-Zubieta, J. Antonio, Sayre, Eric C., Abrahamowicz, Michal, Esdaile, John M., Lacaille, Diane. Cardiovascular Disease Prevention in Rheumatoid Arthritis: Compliance with Diabetes Screening Guidelines. The Journal of rheumatology, vol.45, no.10, 1367-1374.
Austin, Peter C., Stuart, Elizabeth A.. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in medicine, vol.34, no.28, 3661-3679.
Glynn, Robert J., Schneeweiss, Sebastian, Stürmer, Til. Indications for Propensity Scores and Review of their Use in Pharmacoepidemiology. Basic & clinical pharmacology & toxicology, vol.98, no.3, 253-259.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.